Patents by Inventor Charles R. Mackay
Charles R. Mackay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
NOVEL GENES ENCODING PROTEINS HAVING PROGNOSTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES
Publication number: 20120045777Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.Type: ApplicationFiled: June 27, 2011Publication date: February 23, 2012Applicant: Millennium Pharmaceuticals, Inc.Inventors: Christopher C. Fraser, Thomas M. Barnes, John D. Sharp, Susan J. Kirst, Paul S. Myers, Kevin R. Leiby, Douglas A. Holtzman, Sean A. McCarthy, Nicholas Wrighton, Charles R. Mackay, Andrew D.J. Goodearl -
Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
Publication number: 20100291579Abstract: The invention provides isolated nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: July 1, 2010Publication date: November 18, 2010Inventors: Christopher C. Fraser, Sean Anthony McCarthy, John D. Sharp, Thomas M. Barnes, Nicholas C. Wrighton, Charles R. Mackay, Kevin R. Leiby, Douglas A. Holtzman -
Publication number: 20100061983Abstract: The present invention relates to proteins or polypeptides, referred to herein as isolated and/Or recombinant mammalian (e.g., human) IP-10/Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and variants thereof, including those characterized by selective binding of one or more chemokines (e.g., IP-10 and/or Mig), and/or the ability to induce a cellular response (e.g., chemotaxis, exocytosis). Antibodies reactive with CXCR3 receptors can be produced using the proteins or variants thereof or host cells comprising same as immunogen.Type: ApplicationFiled: September 21, 2007Publication date: March 11, 2010Applicants: Millennium Pharmaceuticals, Inc., Theodor-Kocher InstituteInventors: Marcel Loetscher, Bernhard Moser, Shixin Qin, Charles R. Mackay
-
Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
Publication number: 20100062487Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.Type: ApplicationFiled: May 8, 2009Publication date: March 11, 2010Inventors: Christopher C. Fraser, Thomas M. Barnes, John D. Sharp, Susan J. Kirst, Paul S. Myers, Kevin R. Leiby, Douglas A. Holtzman, Sean A. McCarthy, Nicholas Wrighton, Charles R. Mackay, Andrew D.J. Goodearl -
Publication number: 20090286956Abstract: The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted.Type: ApplicationFiled: October 12, 2007Publication date: November 19, 2009Inventors: Sean A. McCarthy, David P. Gearing, Douglas A. Holtzman, Yang Pan, Samantha J. Busfield, Thomas M. Barnes, Charles R. Mackay, Jose M. Lora
-
Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
Publication number: 20090220977Abstract: The invention provides isolated nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: January 9, 2009Publication date: September 3, 2009Inventors: Christopher C. Fraser, Sean Anthony McCarthy, John D. Sharp, Thomas M. Barnes, Nicholas C. Wrighton, Charles R. Mackay, Kevin R. Leiby, Douglas A. Holtzman -
Publication number: 20080220495Abstract: The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted.Type: ApplicationFiled: October 12, 2007Publication date: September 11, 2008Inventors: Sean A. McCarthy, David P. Gearing, Douglas A. Holtzman, Yang Pan, Samantha J. Busfield, Thomas M. Barnes, Charles R. Mackay, Jose M. Lora
-
Patent number: 7407655Abstract: The present invention relates to proteins or polypeptides, referred to herein as isolated and/or recombinant mammalian (e.g., human) IP-10/Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and variants thereof, including those characterized by selective binding of one or more chemokines (e.g., IP-10 and/or Mig), and/or the ability to induce a cellular response (e.g., chemotaxis, exocytosis). Antibodies reactive with CXCR3 receptors can be produced using the proteins or variants thereof or host cells comprising same as immunogen.Type: GrantFiled: September 20, 2002Date of Patent: August 5, 2008Assignees: Millennium Pharmaceuticals, Inc., Theodor-Kocher InstituteInventors: Marcel Loetscher, Bernhard Moser, Shixin Qin, Charles R. Mackay
-
Patent number: 7402657Abstract: The present invention relates to isolated and/or recombinant C-C Chemokine Receptor 3 (CKR-3, CCR3) proteins or polypeptides.Type: GrantFiled: August 31, 2005Date of Patent: July 22, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventors: Craig J. Gerard, Norma P. Gerard, Charles R. Mackay, Paul D. Ponath, Theodore W. Post, Shixin Qin
-
Patent number: 7012133Abstract: The present invention relates to isolated and/or recombinant nucleic acids which encode a mammalian (e.g., human) receptor protein designated C—C Chemokine Receptor 3 (CKR-3) or Eos L2, and to proteins or polypeptides, referred to herein as isolated, recombinant mammalian CKR-3 receptors. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a receptor protein of the present invention or a portion thereof; to host cells comprising such constructs, useful for the production of recombinant CKR-3 receptors or polypeptides; and to antibodies reactive with the receptors, which are useful in research and diagnostic applications. Also provided are methods of use of the nucleic acids, proteins, and host cells to identify ligands, inhibitors (e.g., antagonists) or promoters (agonists) of receptor function.Type: GrantFiled: November 3, 1997Date of Patent: March 14, 2006Assignees: Children's Medical Center Corp., Millennium Pharmaceuticals, Inc., Brigham & Women's HospitalInventors: Craig J. Gerard, Norma P. Gerard, Charles R. Mackay, Paul D. Ponath, Theodore W. Post, Shixin Qin
-
Patent number: 6994977Abstract: The present invention relates to a method of identifying an inhibitor of a mammalian (e.g., human) C—C chemokine receptor 3 (CCR3), comprising combining (a) a compound to be tested, (b) a host cell expressing a recombinant protein comprising a mammalian CCR3, and (c) a ligand of said receptor, under conditions suitable for binding of ligand to said receptor, and detecting or measuring the formation of a receptor-ligand complex. Inhibition of complex formation by the compound is indicative that the compound is an inhibitor.Type: GrantFiled: October 28, 2002Date of Patent: February 7, 2006Assignees: Children's Medical Center Corporation, Millennium Pharmaceuticals, Inc., Brigham & Women's HospitalInventors: Craig J. Gerard, Norma P. Gerard, Charles R. Mackay, Paul D. Ponath, Theodore W. Post, Shixin Qin
-
Patent number: 6806061Abstract: The present invention relates to isolated and/or recombinant nucleic acids which encode a mammalian (e.g., human) receptor protein designated C-C Chemokine Receptor 3 (CKR-3) or Eos L2, and to proteins or polypeptides, referred to herein as isolated, recombinant mammalian CKR-3 receptors. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a receptor protein of the present invention or a portion thereof, and to host cells comprising such constructs, useful for the production of recombinant CKR-3 receptors or polypeptides.Type: GrantFiled: January 19, 1995Date of Patent: October 19, 2004Assignees: Children's Medical Center Corporation, Millennium Pharmaceuticals, Inc., Brigham and Women's HospitalInventors: Craig J. Gerard, Norma P. Gerard, Charles R. Mackay, Paul D. Ponath, Theodore W. Post, Shixin Qin
-
Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
Publication number: 20040121396Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.Type: ApplicationFiled: December 19, 2003Publication date: June 24, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventors: Christopher C. Fraser, Thomas M. Barnes, John D. Sharp, Susan J. Kirst, Paul S. Myers, Kevin R. Leiby, Douglas A. Holtzman, Sean A. McCarthy, Nicholas Wrighton, Charles R. MacKay, Andrew D.J. Goodearl -
Publication number: 20030166870Abstract: The present invention relates to an antibody or functional portion thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 5 protein (CKR-5 or CCR5) or portion of the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR5 with a ligand thereof. Another aspect of the invention relates to a method of inhibiting HIV infection of a cell which expresses a mammalian CCR5 or portion thereof using the antibodies described herein. Also encompassed by the present invention are methods of treating or preventing HIV in a patient.Type: ApplicationFiled: May 30, 2001Publication date: September 4, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Lijun Wu, Charles R. Mackay
-
Publication number: 20030167485Abstract: The present invention provides GPR56 genes and polypeptides encoded therefor. The GPR56 genes of the invention are expressed highly in malignant tissues and the invention also provides diagnostic processes for detecting cancer or malignant tumors in human subjects The diagnostic and prognostic test of the present invention is particularly useful for the early detection of ovarian cancer or metastases thereof and for monitoring the progress of disease, such as, for example, during remission or following surgery or chemotherapy. The GPR56 gene of the invention is also expressed in effector memory T cells, and the invention therefor provides methods of identifying and/or quantifying effector memory T cells, which methods are useful for determining the immune status of a subject.Type: ApplicationFiled: February 12, 2002Publication date: September 4, 2003Applicant: Garvan Institute of Medical ResearchInventors: Herbert Herzog, Robert Lyndsay Sutherland, Charles R. MacKay, Susan Henshall
-
Publication number: 20030158392Abstract: The present invention relates to proteins or polypeptides, referred to herein as isolated and/or recombinant mammalian (e.g., human) IP-10/Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and variants thereof, including those characterized by selective binding of one or more chemokines (e.g., IP-10 and/or Mig), and/or the ability to induce a cellular response (e.g., chemotaxis, exocytosis). Antibodies reactive with CXCR3 receptors can be produced using the proteins or variants thereof or host cells comprising same as immunogen.Type: ApplicationFiled: September 20, 2002Publication date: August 21, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Marcel Loetscher, Bernhard Moser, Shixin Qin, Charles R. Mackay
-
Publication number: 20030143684Abstract: The present invention relates to a method of identifying an inhibitor of a mammalian (e.g., human) C-C chemokine receptor 3 (CCR3), comprising combining (a) a compound to be tested, (b) a host cell expressing a recombinant protein comprising a mammalian CCR3, and (c) a ligand of said receptor, under conditions suitable for binding of ligand to said receptor, and detecting or measuring the formation of a receptor-ligand complex. Inhibition of complex formation by the compound is indicative that the compound is an inhibitor.Type: ApplicationFiled: October 28, 2002Publication date: July 31, 2003Applicants: Children's Medical Center Corporation, Brigham & Women's Hospital, Millennium Pharmaceuticals, Inc.Inventors: Craig J. Gerard, Norma P. Gerard, Charles R. Mackay, Paul D. Ponath, Theodore W. Post, Shixin Qin
-
Patent number: 6537764Abstract: The present invention relates to a method of identifying an inhibitor of a mammalian (e.g., human) C—C chemokine receptor 3 (CCR3), comprising combining (a) a compound to be tested, (b) a host cell expressing a recombinant protein comprising a mammalian CCR3, and (c) a ligand of said receptor, under conditions suitable for binding of ligand to said receptor, and detecting or measuring the formation of a receptor-ligand complex. Inhibition of complex formation by the compound is indicative that the compound is an inhibitor.Type: GrantFiled: September 30, 1996Date of Patent: March 25, 2003Assignees: Children's Medical Center Corporation, Millennium Pharmaceuticals, Inc., Brigham & Women's HospitalInventors: Craig J. Gerard, Norma P. Gerard, Charles R. Mackay, Paul D. Ponath, Theodore W. Post, Shixin Qin
-
Patent number: 6528625Abstract: The present invention relates to an antibody or functional portion thereof which binds to a mammalian (e.g., human) chemokine receptor 5 protein (CKR-5 or CCR5) or portion of the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR5 with a ligand thereof. Another aspect of the invention relates to a method of inhibiting HIV infection of a cell which expresses a mammalian CCR5 or portion thereof using the antibodies described herein. Also encompassed by the present invention are methods of treating or preventing HIV in a patient.Type: GrantFiled: July 11, 1997Date of Patent: March 4, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Lijun Wu, Charles R. Mackay
-
Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
Publication number: 20030022279Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.Type: ApplicationFiled: January 12, 2001Publication date: January 30, 2003Inventors: Christopher C. Fraser, Thomas M. Barnes, John D. Sharp, Susan J. Kirst, Paul S. Myers, Kevin R. Leiby, Douglas A. Holtzman, Sean A. McCarthy, Nicholas Wrighton, Charles R. MacKay, Andrew D.J. Goodearl